Acasti Pharma Receives Japanese, Taiwanese and Mexican Patents

Acasti Pharma (CVE:ACO) has recently received a composition and use patent from the Japanese, Taiwanese and Mexican patent offices.
According to the press release:

The patents are all valid until 2030 and relate to concentrated therapeutic phospholipid omega-3 compositions covering methods for treating or preventing diseases associated with cardiovascular diseases, metabolic syndrome, inflammation, neurodevelopmental diseases and neurodegenerative diseases. They are in addition to multiple other ones Acasti has been granted in the United States, China, Australia, Mexico, Saudi Arabia, Panama and South Africa for phospholipid composition. As well, similar patent applications are being pursued in many jurisdictions worldwide.
“The grant of these new patents is another value-enhancing milestone, which further heightens the potential commercial implications, including possible licensing and partnership opportunities for CaPre and Onemia,” highlighted Pierre Lemieux, PhD, Acasti’s chief operating officer. “We are committed to building our global portfolio of patents to ensure we have very long-lasting and comprehensive protection, while also safeguarding valuable market expansion opportunities.”

Click here to read the full press release.